Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept for macular edema secondary to CRVO/HRVO
CTR20160181Phase 3Completed
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Mar 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in central retinal vein occlusion with macular edema, macular edema, sponsored by Chengdu Kanghong Biotechnology Co., Ltd.. Started Mar 2016; status: completed.
02
Drugs
conbercept
03
Conditions
central retinal vein occlusion with macular edemamacular edema
Beyond the preview
Go deeper on CTR20160181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160181.